 |
471 Diseases |  |
207 Trials |
|
207 Trials |  |
10577 News |  |
| «12...112113114115116117118119120121122...132133» |
- ||||| New P2 trial, Metastases: MIRACLE: Everolimus trIal for Advanced prememopausaL Breast Cancer Patients (clinicaltrials.gov) - Dec 10, 2014
P2, N=200, Not yet recruiting, Sponsor: Chinese Academy of Medical Sciences
- everolimus / Generic mfg., mycophenolate sodium / Generic mfg.
Enrollment closed, Biopsy: Tacrolimus/Everolimus Versus Tacrolimus/Enteric-Coated Mycophenolate Sodium (clinicaltrials.gov) - Dec 10, 2014
P3, N=50, Active, not recruiting, Sponsor: Gaetano Ciancio
Recruiting --> Active, not recruiting
- ganitumab (AMG 479) / Takeda, ImmunityBio
Enrollment closed, Trial primary completion date, Combination therapy, Metastases: Study of RAD001 + AMG479 for Patients With Advanced Solid Tumors (clinicaltrials.gov) - Dec 9, 2014
P1, N=30, Active, not recruiting, Sponsor: Indiana University
Recruiting --> Active, not recruiting Recruiting --> Active, not recruiting | Trial primary completion date: Jun 2014 --> Jan 2015
- simvastatin / Generic mfg.
Trial primary completion date: Safety of Simvastatin in LAM and TSC (clinicaltrials.gov) - Dec 6, 2014
P1/2, N=10, Recruiting, Sponsor: University of Pennsylvania
Recruiting --> Active, not recruiting | Trial primary completion date: Jun 2014 --> Jan 2015 Trial primary completion date: Feb 2015 --> Dec 2015
- everolimus / Generic mfg.
New P2 trial, IO biomarker, Metastases: A Biological Prospective Study in Patients With Metastatic Pancreatic NETs Treated With Everolimus (clinicaltrials.gov) - Dec 6, 2014
P2, N=47, Recruiting, Sponsor: European Institute of Oncology
- | everolimus / Generic mfg.
Enrollment open: EVERKYSTE: The Efficacy of Everolimus in Reducing Total Native Kidney Volume in Polycystic Kidney Disease Transplanted Recipients (clinicaltrials.gov) - Dec 6, 2014
P3, N=40, Recruiting, Sponsor: Assistance Publique - Hôpitaux de Paris
Trial primary completion date: Feb 2015 --> Dec 2015 Not yet recruiting --> Recruiting
- || Votrient (pazopanib) / Novartis, BeiGene
Trial primary completion date, Metastases: Pazopanib and Everolimus in PI3KCA Mutation Positive/PTEN Loss Patients (clinicaltrials.gov) - Dec 6, 2014
P1, N=62, Active, not recruiting, Sponsor: M.D. Anderson Cancer Center
Not yet recruiting --> Recruiting Trial primary completion date: Oct 2015 --> Oct 2016
- |||| everolimus / Generic mfg.
Enrollment open, Metastases: Phase II Study of Everolimus Beyond Progression (clinicaltrials.gov) - Dec 6, 2014
P2, N=70, Recruiting, Sponsor: Emory University
Trial primary completion date: Oct 2015 --> Oct 2016 Not yet recruiting --> Recruiting
- | Farydak (panobinostat) / Secura Bio, Sutent (sunitinib) / Pfizer
Enrollment open, Trial primary completion date, Combination therapy, Metastases: Panobinostat and Everolimus in Treating Patients With Metastatic or Unresectable Renal Cell Cancer That Does Not Respond to Treatment With Sunitinib Malate or Sorafenib Tosylate (clinicaltrials.gov) - Dec 6, 2014
P1/2, N=48, Recruiting, Sponsor: Roswell Park Cancer Institute
Not yet recruiting --> Recruiting Active, not recruiting --> Recruiting | Trial primary completion date: Nov 2014 --> Jun 2017
- everolimus / Generic mfg., sirolimus / Generic mfg.
Enrollment change, Trial withdrawal, Trial primary completion date, Combination therapy: DESIRE: Differentiating Everolimus Versus Sirolimus in Combination With Calcineurin Inhibitors in Kidney Transplant Patients (clinicaltrials.gov) - Dec 5, 2014
P4, N=0, Withdrawn, Sponsor: University of Colorado, Denver
Active, not recruiting --> Recruiting | Trial primary completion date: Nov 2014 --> Jun 2017 N=150 --> 0 | Recruiting --> Withdrawn | Trial primary completion date: Dec 2014 --> Jun 2014
- | everolimus / Generic mfg.
Trial completion, Trial primary completion date, Metastases: Everolimus in Treating Patients With Locally Advanced or Metastatic Thyroid Cancer (clinicaltrials.gov) - Dec 5, 2014
P2, N=40, Completed, Sponsor: Yonsei University
N=150 --> 0 | Recruiting --> Withdrawn | Trial primary completion date: Dec 2014 --> Jun 2014 Recruiting --> Completed | Trial primary completion date: Jan 2015 --> Oct 2014
- everolimus / Generic mfg., exemestane / Generic mfg.
Trial primary completion date, Combination therapy, Metastases: 4EVER UK: An Open Label Study of Postmenopausal Women With Oestrogen Receptor Positive Locally Advanced or Metastatic Breast Cancer Treated With Everolimus (RAD001) With Exemestane, With Exploratory Epigenetic Marker Analysis (clinicaltrials.gov) - Dec 5, 2014
P4, N=50, Active, not recruiting, Sponsor: Novartis Pharmaceuticals
Recruiting --> Completed | Trial primary completion date: Jan 2015 --> Oct 2014 Trial primary completion date: Dec 2014 --> Jun 2015
- Herceptin (trastuzumab) / Roche
Trial primary completion date, Combination therapy: A Study Of Everolimus, Trastuzumab And Vinorelbine In HER2-Positive Breast Cancer Brain Metastases (clinicaltrials.gov) - Dec 5, 2014
P2, N=35, Recruiting, Sponsor: UNC Lineberger Comprehensive Cancer Center
Trial primary completion date: Dec 2014 --> Jun 2015 Trial primary completion date: Dec 2014 --> Dec 2015
- || Herceptin (trastuzumab) / Roche
Trial primary completion date, Metastases: Phase II Trial of EVEROLIMUS (clinicaltrials.gov) - Dec 5, 2014
P2, N=80, Recruiting, Sponsor: Emory University
Trial primary completion date: Dec 2014 --> Dec 2015 Trial primary completion date: Oct 2014 --> Oct 2015
- | letrozole / Generic mfg., everolimus / Generic mfg.
Enrollment open: Everolimus and Letrozole in Treating Patients With Recurrent Hormone Receptor Positive Ovarian, Fallopian Tube, or Primary Peritoneal Cavity Cancer (clinicaltrials.gov) - Dec 5, 2014
P2, N=20, Recruiting, Sponsor: Mayo Clinic
Trial primary completion date: Oct 2014 --> Oct 2015 Not yet recruiting --> Recruiting
- | Erbitux (cetuximab) / Eli Lilly, EMD Serono
Trial completion, Enrollment change, Metastases: A Study of Carboplatin, Cetuximab and RAD001 in Advanced Head and Neck Cancer (clinicaltrials.gov) - Dec 5, 2014
P1/2, N=20, Completed, Sponsor: Emory University
Not yet recruiting --> Recruiting Active, not recruiting --> Completed | N=48 --> 20
- |||| everolimus / Generic mfg., cyclosporine / Generic mfg.
Trial primary completion date, Combination therapy: Efficacy, Safety and Tolerability of Everolimus in Combination With Reduced Exposure Cyclosporine or Tacrolimus in Paediatric Liver Transplant Recipients. (clinicaltrials.gov) - Nov 25, 2014
P3, N=75, Recruiting, Sponsor: Novartis Pharmaceuticals
Active, not recruiting --> Completed | N=48 --> 20 Trial primary completion date: Aug 2016 --> Sep 2017
- everolimus / Generic mfg., erlotinib / Generic mfg., dasatinib / Generic mfg.
Enrollment open, IO biomarker: BIOMEDE: Biological Medicine for Diffuse Intrinsic Pontine Glioma (DIPG) Eradication (clinicaltrials.gov) - Nov 25, 2014
P2, N=225, Recruiting, Sponsor: Gustave Roussy, Cancer Campus, Grand Paris
Trial primary completion date: Aug 2016 --> Sep 2017 Not yet recruiting --> Recruiting
- |||| dactolisib (RTB101) / Adicet Bio
Trial completion, Enrollment change, Metastases: Efficacy and Safety of BEZ235 Compared to Everolimus in Patients With Advanced Pancreatic Neuroendocrine Tumors (clinicaltrials.gov) - Nov 24, 2014
P2, N=62, Completed, Sponsor: Novartis Pharmaceuticals
Not yet recruiting --> Recruiting Recruiting --> Completed | N=140 --> 62
- | Avastin (bevacizumab) / Roche
Trial completion, Enrollment change, Trial primary completion date, Metastases: Study of Everolimus, Pemetrexed, Carboplatin, and Bevacizumab to Treat Stage IV Lung Cancer (clinicaltrials.gov) - Nov 24, 2014
P1, N=13, Completed, Sponsor: Cancer Research and Biostatistics Clinical Trials Consortium
Recruiting --> Completed | N=140 --> 62 Recruiting --> Completed | N=24 --> 13 | Trial primary completion date: Mar 2015 --> Oct 2014
- | everolimus / Generic mfg., erlotinib / Generic mfg.
Trial completion, Enrollment change, Trial primary completion date: Trial of RAD001 and Erlotinib With Recurrent Head and Neck Squamous Cell Carcinoma (clinicaltrials.gov) - Nov 23, 2014
P2, N=49, Completed, Sponsor: M.D. Anderson Cancer Center
Recruiting --> Completed | N=24 --> 13 | Trial primary completion date: Mar 2015 --> Oct 2014 Active, not recruiting --> Completed | N=35 --> 49 | Trial primary completion date: Jan 2016 --> Nov 2014
- everolimus / Generic mfg.
Biomarker, Trial termination, Trial primary completion date: Study of Everolimus Added to Combined Hormonal and Radiation Therapy for High Risk Prostate Cancer (clinicaltrials.gov) - Nov 20, 2014
P1, N=1, Terminated, Sponsor: University of Michigan Cancer Center
Active, not recruiting --> Completed | N=35 --> 49 | Trial primary completion date: Jan 2016 --> Nov 2014 Withdrawn --> Terminated | Trial primary completion date: Apr 2023 --> Aug 2014; Lack of accrual and funding expires in June, 2014.
- everolimus / Generic mfg.
Enrollment closed: Study of Everolimus in Patients With Thymoma and Thymic Carcinoma Previously Treated With Chemotherapy (clinicaltrials.gov) - Nov 20, 2014
P2, N=41, Active, not recruiting, Sponsor: Armando Santoro, MD
Withdrawn --> Terminated | Trial primary completion date: Apr 2023 --> Aug 2014; Lack of accrual and funding expires in June, 2014. Recruiting --> Active, not recruiting
- Sandostatin LAR Depot (octreotide acetate) / Novartis
New P2 trial, Combination therapy, Metastases: MetNET1: Activity and Safety of Everolimus+Octreotide LAR+Metformin in Advanced Pancreatic Well-differentiated NETs (clinicaltrials.gov) - Nov 19, 2014
P2, N=43, Recruiting, Sponsor: Fondazione IRCCS Istituto Nazionale dei Tumori, Milano
- dactolisib (RTB101) / Adicet Bio
Trial primary completion date, Combination therapy, Metastases: Dose Finding Study of RAD001 (Everolimus, Afinitor (clinicaltrials.gov) - Nov 19, 2014
P1, N=46, Active, not recruiting, Sponsor: Novartis Pharmaceuticals
Recruiting --> Active, not recruiting Trial primary completion date: Aug 2014 --> Apr 2015
- Avastin (bevacizumab) / Roche
Trial primary completion date: Everolimage: Vascular Endothelial Growth Factor (VEGF) Imaging Before and During Everolimus Treatment for Renal Cell Carcinoma (clinicaltrials.gov) - Nov 19, 2014
P=N/A, N=14, Recruiting, Sponsor: University Medical Centre Groningen
Trial primary completion date: Aug 2014 --> Apr 2015 Trial primary completion date: Oct 2014 --> Feb 2015
- |||| anastrozole / Generic mfg., everolimus / Generic mfg., exemestane / Generic mfg.
Trial primary completion date, Combination therapy, Metastases: BOLERO-2: Everolimus in Combination With Exemestane in the Treatment of Postmenopausal Women With Estrogen Receptor Positive Locally Advanced or Metastatic Breast Cancer Who Are Refractory to Letrozole or Anastrozole (clinicaltrials.gov) - Nov 19, 2014
P3, N=723, Active, not recruiting, Sponsor: Novartis Pharmaceuticals
Trial primary completion date: Oct 2014 --> Feb 2015 Trial primary completion date: Feb 2011 --> Dec 2014
- ||| Avastin (bevacizumab) / Roche, Vectibix (panitumumab) / Amgen
Trial completion, Enrollment change, Metastases: BEP Study Phase I (Bevacizumab, Everolimus, Panitumumab) (clinicaltrials.gov) - Nov 19, 2014
P1, N=56, Completed, Sponsor: Herbert Hurwitz, MD
Trial primary completion date: Feb 2011 --> Dec 2014 Active, not recruiting --> Completed | N=44 --> 56
- Avastin (bevacizumab) / Roche
Trial completion, Enrollment change, Combination therapy, Metastases: Bevacizumab, Everolimus, and Erlotinib in Treating Patients With Advanced Solid Tumors (clinicaltrials.gov) - Nov 19, 2014
P1, N=65, Completed, Sponsor: Herbert Hurwitz, MD
Active, not recruiting --> Completed | N=44 --> 56 Active, not recruiting --> Completed | N=40 --> 65
- |||| Inlyta (axitinib) / Pfizer, Sutent (sunitinib) / Pfizer
Enrollment open, Phase classification, HEOR, Real-world evidence, Real-world, Metastases: ADONIS: Study Of The Impact Of Inlyta In 2nd Line On The Treatment Outcomes Of mRCC Patients Treated With Sutent In 1st Line In The Real Life Setting (clinicaltrials.gov) - Nov 18, 2014
P4, N=750, Enrolling by invitation, Sponsor: Pfizer
Active, not recruiting --> Completed | N=40 --> 65 Not yet recruiting --> Enrolling by invitation | Phase classification: PN/A --> P4
- |||| everolimus / Generic mfg.
Trial completion, Trial primary completion date: Umbrella: A Facilitated Access Program to Provide Everolimus (RAD) Maintenance for Patients Completing Therapy in RAD Trials in Solid Organ Transplantation (clinicaltrials.gov) - Nov 17, 2014
P4, N=1025, Completed, Sponsor: Novartis Pharmaceuticals
Not yet recruiting --> Enrolling by invitation | Phase classification: PN/A --> P4 Active, not recruiting --> Completed | Trial primary completion date: Dec 2016 --> Feb 2014
- | everolimus / Generic mfg.
New P2 trial, Combination therapy, Metastases: Everolimus Combined With Anti-estrogen Therapy in Hormone-Receptor-Positive HER-2 Negative Advanced Breast Cancer (clinicaltrials.gov) - Nov 17, 2014
P2, N=46, Not yet recruiting, Sponsor: SCRI Development Innovations, LLC
- | everolimus / Generic mfg.
Trial completion, Trial primary completion date, Monotherapy, Surgery: NFitor: Use of RAD001 as Monotherapy in the Treatment of Neurofibromatosis 1 Related Internal Plexiform Neurofibromas (clinicaltrials.gov) - Nov 14, 2014
P2, N=30, Completed, Sponsor: Assistance Publique - Hôpitaux de Paris
Active, not recruiting --> Completed | Trial primary completion date: Dec 2016 --> Feb 2014 Active, not recruiting --> Completed | Trial primary completion date: Jan 2014 --> Oct 2013
- | Signifor (pasireotide) / Recordati
Enrollment closed, Enrollment change: Pasireotide, Everolimus and Selective Internal Radioembolization Therapy for Unresectable Hepatic Metastases (clinicaltrials.gov) - Nov 14, 2014
P1/2, N=13, Active, not recruiting, Sponsor: Emory University
Active, not recruiting --> Completed | Trial primary completion date: Jan 2014 --> Oct 2013 Recruiting --> Active, not recruiting | N=49 --> 13
- Signifor LAR (pasireotide long acting release) / Recordati
Enrollment closed, Enrollment change, Combination therapy, Metastases: Evaluate Safety and Tolerability of Pasireotide LAR in Combination With Everolimus in Advanced Metastatic NETs (clinicaltrials.gov) - Nov 13, 2014
P1, N=17, Active, not recruiting, Sponsor: Novartis Pharmaceuticals
Recruiting --> Active, not recruiting | N=49 --> 13 Recruiting --> Active, not recruiting | N=60 --> 17
- | retaspimycin (IPI-504) / Infinity Pharma
Trial completion, Enrollment change, Combination therapy: Phase 1b/2 Study of Retaspimycin HCl (IPI-504) in Combination With Everolimus in KRAS Mutant Non-small Cell Lung Cancer (clinicaltrials.gov) - Nov 13, 2014
P1/2, N=47, Completed, Sponsor: Infinity Pharmaceuticals, Inc.
Recruiting --> Active, not recruiting | N=60 --> 17 Active, not recruiting --> Completed | N=70 --> 47
- Odomzo (sonidegib) / Sun Pharma
Enrollment open, Combination therapy, Metastases: LDE225 + Everolimus in Advanced Gastroesophageal Adenocarcinoma (clinicaltrials.gov) - Nov 12, 2014
P1, N=42, Recruiting, Sponsor: M.D. Anderson Cancer Center
Active, not recruiting --> Completed | N=70 --> 47 Not yet recruiting --> Recruiting
- ||||| Cabometyx (cabozantinib tablet) / Exelixis
Enrollment closed, Metastases: METEOR: A Study of Cabozantinib (XL184) vs Everolimus in Subjects With Metastatic Renal Cell Carcinoma (clinicaltrials.gov) - Nov 11, 2014
P3, N=650, Active, not recruiting, Sponsor: Exelixis
Not yet recruiting --> Recruiting Recruiting --> Active, not recruiting
- || everolimus / Generic mfg.
Trial primary completion date: INPRES: Influence of Exceptional Patient Characteristics on Everolimus Exposure (clinicaltrials.gov) - Nov 6, 2014
P4, N=75, Recruiting, Sponsor: Radboud University
Recruiting --> Active, not recruiting Trial primary completion date: Sep 2015 --> Sep 2016
- lapatinib / Generic mfg., everolimus / Generic mfg.
Trial primary completion date, Metastases: Lapatinib and RAD-001 for HER2 Positive Metastatic Breast Cancer (clinicaltrials.gov) - Nov 6, 2014
P2, N=45, Recruiting, Sponsor: University of Kansas
Trial primary completion date: Sep 2015 --> Sep 2016 Trial primary completion date: Nov 2014 --> Nov 2015
- everolimus / Generic mfg.
Enrollment open, Trial initiation date: Prediction of Everolimus-induced Interstitial Lung Disease (clinicaltrials.gov) - Nov 6, 2014
P=N/A, N=100, Recruiting, Sponsor: Radboud University
Trial primary completion date: Nov 2014 --> Nov 2015 Not yet recruiting --> Recruiting | Initiation date: Dec 2013 --> May 2014
- ||||||| everolimus / Generic mfg.
Trial completion: Efficacy and Safety of Everolimus (RAD001) in Patients of All Ages With Subependymal Giant Cell Astrocytoma Associated With Tuberous Sclerosis Complex (TSC)(EXIST-1) (clinicaltrials.gov) - Nov 6, 2014
P3, N=118, Completed, Sponsor: Novartis Pharmaceuticals
Not yet recruiting --> Recruiting | Initiation date: Dec 2013 --> May 2014 Active, not recruiting --> Completed
- everolimus / Generic mfg.
Trial primary completion date, Metastases: OSAT: A Norwegian Observational Trial Evaluating the Treatment of Advanced Renal Cell Cancer Patients Under Treatment of Afinitor (clinicaltrials.gov) - Nov 5, 2014
P=N/A, N=30, Recruiting, Sponsor: Novartis Pharmaceuticals
Active, not recruiting --> Completed Trial primary completion date: Dec 2013 --> Dec 2015
- || everolimus / Generic mfg.
Trial primary completion date, Monotherapy, Metastases: RAMSETE/CDE16: RAMSETE: RAD001 in Advanced and Metastatic Silent Neuro-endocrine Tumors in Europe (clinicaltrials.gov) - Nov 5, 2014
P2, N=60, Recruiting, Sponsor: Novartis Pharmaceuticals
Trial primary completion date: Dec 2013 --> Dec 2015 Trial primary completion date: Dec 2013 --> Dec 2014
- | letrozole / Generic mfg., everolimus / Generic mfg.
New P2 trial: Everolimus and Letrozole in Treating Patients With Recurrent Hormone Receptor Positive Ovarian, Fallopian Tube, or Primary Peritoneal Cavity Cancer (clinicaltrials.gov) - Nov 5, 2014
P2, N=20, Not yet recruiting, Sponsor: Mayo Clinic
- | everolimus / Generic mfg.
Enrollment open: Pharmacokinetically Guided Everolimus in Patients With Breast Cancer, Pancreatic Neuroendocrine Tumors, or Kidney Cancer (clinicaltrials.gov) - Nov 5, 2014
P2, N=26, Recruiting, Sponsor: Emory University
Trial primary completion date: Dec 2013 --> Dec 2014 Not yet recruiting --> Recruiting
- | everolimus / Generic mfg.
Enrollment closed, Enrollment change, Trial primary completion date, Monotherapy: Study of RAD001 for Treatment of NF2-related Vestibular Schwannoma (clinicaltrials.gov) - Nov 5, 2014
P2, N=25, Active, not recruiting, Sponsor: University of California, Los Angeles
Not yet recruiting --> Recruiting Recruiting --> Active, not recruiting | N=10 --> 25 | Trial primary completion date: Jan 2015 --> Feb 2017
- | cisplatin / Generic mfg., everolimus / Generic mfg.
Trial completion, Metastases: PHOENIX I: A Study of mTOR Inhibitor Everolimus (RAD001) in Association With Cisplatin and Radiotherapy for Locally Advanced Cervix Cancer (clinicaltrials.gov) - Nov 5, 2014
P1, N=14, Completed, Sponsor: Novartis Pharmaceuticals
Recruiting --> Active, not recruiting | N=10 --> 25 | Trial primary completion date: Jan 2015 --> Feb 2017 Recruiting --> Completed
- Vectibix (panitumumab) / Amgen
Trial primary completion date, Metastases: Safety Study of the Combination of Panitumumab, Irinotecan and Everolimus in the Treatment of Advanced Colorectal Cancer (clinicaltrials.gov) - Nov 4, 2014
P1/2, N=50, Recruiting, Sponsor: The Queen Elizabeth Hospital
Recruiting --> Completed Trial primary completion date: Jun 2012 --> Jun 2015
- |||| everolimus / Generic mfg.
Enrollment open, Combination therapy: Neoadj ph 2 AI Plus Everolimus in Postmenopausal Women w/ ER Pos/HER2 Neg, Low Risk Score (clinicaltrials.gov) - Nov 4, 2014
P2, N=66, Recruiting, Sponsor: Yale University
Trial primary completion date: Jun 2012 --> Jun 2015 Not yet recruiting --> Recruiting